DBV Technologies S.A. files 10-K

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing a patch-based immunotherapy for food allergies. The company incurred a net loss of $146.9 million in 2025, an increase from $113.9 million in 2024, as it continues to invest heavily in research and development and prepare for the potential commercial launch of its lead product candidate, Viaskin Peanut. The company secured significant financing in 2025 and early 2026, which management believes provides sufficient liquidity to fund operations into the second quarter of 2027.